References
- Ramchandren R, Schiffer CA. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. Biologics 2009;3:205-14
- Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia. Cancer 2011;117:897-906
- National Comprehensive Cancer Network Guidelines. Chronic myelogenous leukemia. v. 2.2017. January 19, 2017. Fort Washington, PA. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf Accessed January 20, 2017
- Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011;25:201-10
- Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. Am J Hematol 2015;90:E66-72
- US Food and Drug Administration. What is a serious adverse event? Silver Spring, MD. http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm Accessed January 20, 2017
- Harpaz R, DuMouchel W, LePendu P, et al. Performance of pharmacovigilance signal detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther 2013;93:539-46
- MedDRA Maintenance and Support Services Organization. Introductory guide to MedDRA Version 15.0. Publication no. MSSO-DI-6003-15.0.0. Chantilly, VA: International Federation of Pharmaceutical Manufacturers and Associations; 2012
- Russo CA, Andrews RM. Healthcare Cost and Utilization Project. Statistical Brief #51. Hospital stays for stroke and other cerebrovascular diseases, 2005. May 2008. Rockville, MD. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb51.jsp Accessed January 20, 2017
- Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes 2010;3:642-51